Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

Free Publication Certificate

Vol. 10, Issue 3 (2021)

Genotoxicity assessment of andrographolide in Ames mutagenicity assay and in vitro chromosomal aberration assay

Author(s):
Srinivasan MR, SP Preetha, GV Sudhakar Rao, KG Tirumurugaan, A Seshiah and S Ramesh
Abstract:
Andrographis paniculata (Burm.f.) Nees. is a medicinal herb widely used in various traditional medicines for the treatment of various ailments particularly related to viral fever, respiratory tract infections, and other pharmacological properties. Andrographolide is a diterpene present as a major active ingredient responsible for various pharmacological activities. This study was conducted to assess the mutagenicity and clastogenicity potential of the andrographolide by Ames mutagenicity and in vitro chromosomal aberration studies, respectively.
Materials and Methods: Ames Mutagenicity assay was performed using Salmonella typhimurium strains, TA100, TA1535, TA102 and TA98 and TA1537 and in vitro chromosomal aberration study was performed in CHO-K1 cell line. Both these studies were conducted following the procedure mentioned in the OECD guidelines no. 471 and 473 for Ames and in vitro chromosomal aberration studies, respectively.
Results: Andrographolide was found to be non-mutagenic in Ames mutagenicity assay and non-clastogenic in the in vitro chromosomal aberration study in the CHO-K1 cell line.
Pages: 61-65  |  517 Views  94 Downloads


The Pharma Innovation Journal
How to cite this article:
Srinivasan MR, SP Preetha, GV Sudhakar Rao, KG Tirumurugaan, A Seshiah, S Ramesh. Genotoxicity assessment of andrographolide in Ames mutagenicity assay and in vitro chromosomal aberration assay. Pharma Innovation 2021;10(3):61-65.
Important Publications Links
The Pharma Innovation Journal

The Pharma Innovation Journal


Call for book chapter